Market Wire - The 340B Prime Vendor Program Adds AstraZeneca’s Cholesterol-Lowering Medication Crestor(R) to Its List of Branded Drugs Available for Participants
CHESHIRE, England, November 1 /PRNewswire/ — New data published today in the American Journal of Cardiology add to a growing body of data that CRESTOR(R) (rosuvastatin calcium) may improve kidney function. The study, Effect of Rosuvastatin on C-Reactive Protein and Renal Function in Patients with Chronic Kidney Disease, shows that CRESTOR 10 mg has favourable anti-inflammatory effects in patients with chronic kidney disease and is supportive of potential accompanying renoprotective benefits.
Related Results
Evening Standard, London, Market Report Column.
US scientist casts doubt on AstraZeneca’s Crestor
AstraZeneca’s Crestor off to strong start in USA; overall performance on track.
AstraZeneca warns of delay to Crestor launch
US scientist casts doubt on AstraZeneca’s Crestor
The purpose of this 20-week, open-label, randomized clinical trial was to evaluate …
Read the rest of this article with a Free Trial at HighBeam Research.
